Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors

@article{Hara2011PrevalenceOS,
  title={Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors},
  author={Hiroto Hara and Takashi Hironaka and Makoto Inoue and Akihiro Iida and Tsugumine Shu and Mamoru Hasegawa and Yoshiyuki Nagai and Ann R. Falsey and Anatoli Kamali and Omu Anzala and Eduard J Sanders and Etienne Karita and Lawrence M Mwananyanda and Sandhya Vasan and Angela Lombardo and Christopher L. Parks and Eddy Sayeed and Marietta Krebs and Emmanuel G. Cormier and James Ackland and Matthew A. Price and Jean-Louis Excler},
  journal={Human Vaccines},
  year={2011},
  volume={7},
  pages={639 - 645}
}
A Sendai virus (SeV) vector is being developed for delivery of an HIV immunogen. SeV is not known to cause disease in humans. Because it is genetically and antigenically related to human parainfluenza virus type 1 (hPIV-1), it is important to determine whether pre-existing hPIV-1 antibodies will affect immune responses elicited by a SeV vector-based vaccine. To quantify SeV neutralizing antibodies (NAb) in human serum, a sensitive virus neutralization assay was developed using a SeV vector… 
Immunogenicity of a recombinant Sendai virus expressing the capsid precursor polypeptide of foot-and-mouth disease virus.
TLDR
The results indicated that the recombinant SeV-P1 virus could be utilized as an alternative strategy to develop a new generation of safety and efficacious vaccine against FMDV infection.
Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies.
TLDR
The potential of intranasal SeV vector vaccination to induce CD8(+) T-cell responses even in humans is implied, suggesting a rationale for proceeding to a vaccine clinical trial using this vector.
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease
TLDR
A novel RSV vaccine concept based on a novel genome replication-deficient Sendai virus (SeV) vector that has many favorable vaccine characteristics is provided, suitable for initiating clinical studies, and it could also be applied to other infectious diseases.
The Challenges of Vaccine Development against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector
TLDR
This review outlines approaches for developing vaccines against the new SARS-CoV-2 coronavirus that are based on non-pathogenic viral vectors, since it can be administered intranasally and induce a mucosal immune response that strengthens the antiviral barrier in the respiratory tract and provides reliable protection against infection.
Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization.
TLDR
Intranasal administration of rhPIV2-Ag85B induced Mtb-specific immune responses, and the vaccinated mice showed a substantial reduction in the number of CFU of Mtb in lungs and spleens, which provides further evidence for the possibility ofrhPIV 2-Ag 85B as a novel TB vaccine.
Development of an AIDS vaccine using Sendai virus vectors.
TLDR
The potential of SeV vector as a vaccine antigen delivery tool to induce effective immune responses against HIV-1 infection is described.
Replication-Competent Viral Vectors for Vaccine Delivery
TLDR
This chapter includes a brief description of available viral vector technologies and their contribution to vaccine design, using human immunodeficiency virus vaccine development as a case study.
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens
TLDR
The first-in-human safety and immunogenicity assessment of a prototype intranasally administered, replication-competent Sendai virus (SeV)–vectored, human immunodeficiency virus type 1 (HIV-1) vaccine primed functional, durable HIV-specific T-cell responses and boosted antibody responses.
Development of a Mucosal TB Vaccine Using Human Parainfluenza Type 2 Virus
TLDR
This review shows recent findings related to current and future vaccination strategies against TB, and provides further evidences for the potential usefulness of HPIV2 as a novel nasal vaccine vector that could elicit Mtb-specific systemic and mucosal immunity.
Development of Vaccines Using SeV Vectors Against AIDS and Other Infectious Diseases
TLDR
The potential of a recombinant SeV vector vaccine to efficiently induce antigen-specific cytotoxic T-lymphocyte (CTL) responses, leading to control of viral replication in a macaque AIDS model is shown.
...
1
2
3
...

References

SHOWING 1-10 OF 60 REFERENCES
Comparison of Neutralizing and Hemagglutination-Inhibiting Antibody Responses to Influenza A Virus Vaccination of Human Immunodeficiency Virus-Infected Individuals
TLDR
The neutralizing serum antibody titers to influenza A/Taiwan/1/86 (H1N1) and Beijing/353/89 (H3N2) viruses after vaccination of 51 human immunodeficiency virus type 1-infected individuals and 10 healthy noninfected controls against influenza virus infection correlated well with the hemagglutination-inhibition (HAI) titers.
Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections.
TLDR
Testing of hPIV-3 and RSV candidate vaccines using Sendai virus (SeV, murine PIV-1) as a vector results encourage the continued development of the candidate recombinant SeV vaccines to combat serious respiratory infections of children.
Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques.
TLDR
The feasibility of inducing antigen-specific T-cell responses by SeV vaccination even in the host with pre-existing anti-SeV neutralizing antibodies is suggested.
Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus.
TLDR
The role of the immune response in reducing disease severity is examined; the history of RSV vaccine development is considered; and the potential utility of Sendai virus (a murine paramyxovirus) as a xenogenic vaccine vector for the delivery of RSv antigens is advocated.
Viral cross-reactivity and antigenic determinants recognized by human parainfluenza virus type 1-specific cytotoxic T-cells.
TLDR
It is demonstrated that the human CTL response is directed to multiple determinants within several distinct hPIV-1 proteins, among major antigenic determinants for CTL.
Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.
TLDR
Results identify SeV vectors as promising vaccine candidates for four different paramyxoviruses, each responsible for serious respiratory infections in children.
Antigenic diversity of human parainfluenza virus type 1 isolates and their immunological relationship with Sendai virus revealed by using monoclonal antibodies.
TLDR
Results confirm that although hPIV-1 is related to SV, it is antigenically distinct from it.
Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSV
TLDR
Recombinant SV expressing RSV G glycoprotein was prepared by using reverse genetics, and intranasal inoculation of cotton rats elicited RSV-specific antibody and elicited protection from RSV challenge, creating a promising live virus vaccine candidate for RSV.
Development of Recombinant Sendai Virus Vaccines for Prevention of Human Parainfluenza and Respiratory Syncytial Virus Infections
  • J. Hurwitz
  • Medicine
    The Pediatric infectious disease journal
  • 2008
TLDR
Preclinical studies continue and have demonstrated that intranasal vaccinations with recombinant SV expressing an RSV antigen are sufficient to activate high-magnitude RSV-specific neutralizing B- and T-cell activities in a cotton rat system, and vaccinated animals are completely protected against RSV challenges.
Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B.
TLDR
Experimental results encourage promotion of this recombinant SV construct as a vaccine candidate for the prevention of RSV in humans.
...
1
2
3
4
5
...